Sector News

Careful, European drugmakers. Fitch says M&A may be a bit too heated

April 16, 2015
Life sciences
Fitch Ratings is raising the flag on pharma M&A. The credit ratings agency says the current spate of dealmaking is putting some pressure on European Big Pharma players.
 
No wonder: Competition for promising deals has intensified recently, with prices for some buyouts raising eyebrows among investors and analysts alike. AbbVie’s $21 billion deal for Pharmacyclics may be the most obvious example, but smaller deals have come with big premiums, too.
 
Drugmakers in Europe and Britain have been among the most active buyers in recent months. Pharma giants GlaxoSmithKline and Novartis wrapped up the biggest deal of the year so far, when GSK nabbed Novartis’ vaccines unit, and Novartis bought out GSK’s oncology business–and set up a consumer health joint venture to boot.
 
Meanwhile, Germany’s Bayer bought Merck & Co.’s consumer business for $14 billion, and its fellow German drugmaker Merck KGaA agreed to acquire Sigma-Aldrich for $17 billion. Smaller drugmakers, including Ireland-based Shire, have been on an acquisition binge as well; Shire snapped up NPS Pharmaceuticals in January for $5.2 billion.
 
These deals all have one thing in common: Drugmakers are working to exit businesses they don’t think they can dominate, while building up where they already are strong. Shire’s NPS deal helped beef up its gastrointestinal business, for instance, while Bayer’s consumer health buyout is part of a play to become top dog in that field.
 
The strategy may be sound, but Fitch is warning pharma investors to keep an eye on how drugmakers are financing their buys. “[T]he effects of recent M&A activity continues to negatively affect the ratings headroom for European pharma players,” the ratings agency noted Thursday, “as they seek to position themselves in key treatment areas and consolidate market positions.”
 
It’s not as if it’s a new idea, however. Merck & Co. executives recently remarked that they might prefer using cash to buy back shares, if prices rose too high; even more recently, they announced a $10 billion expansion to the company’s buyback program. And Sanofi ($SNY) Chairman Serge Weinberg told Les Echos that his company can do without dealmaking at today’s prices. In scouting for buys, Sanofi “found the asking prices to be too high for the businesses,” Weinberg told the French pub, adding that the company’s balance of innovation and diversification “makes acquisitions not indispensable.”
 
By Tracy Staton
 

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).